Prognostic factors in patients with metastatic pancreatic adenocarcinoma receiving systemic chemotherapy.
about
Efficacy of infusional 5-fluorouracil, doxorubicin, and mitomycin-C (iFAM) in the treatment of patients with gemcitabine-pretreated pancreatic cancer and analysis of prognostic factors in a salvage setting.Importance of performance status for treatment outcome in advanced pancreatic cancer.Chronic pancreatitis and systemic inflammatory response syndrome prevent impact of chemotherapy with gemcitabine in a genetically engineered mouse model of pancreatic cancer.Prognostic factors for gemcitabine-refractory patients with advanced pancreatic cancer: a retrospective analysis of a multicentre study (Anatolian Society of Medical Oncology).A prognostic index model to predict the clinical outcomes for advanced pancreatic cancer patients following palliative chemotherapy.Yield of clinical and radiographic surveillance in patients with resected pancreatic adenocarcinoma following multimodal therapyPreoperative lymphocyte count as a prognostic factor in resected pancreatic ductal adenocarcinomaPrognostic and therapeutic significance of carbohydrate antigen 19-9 as tumor marker in patients with pancreatic cancer.Systemic inflammatory response predicts outcome in patients undergoing resection for ductal adenocarcinoma head of pancreas.Impact of serum C-reactive protein level on the prognosis of patients with hepatocellular carcinoma undergoing TACE.Treatment outcome of advanced pancreatic cancer patients who are ineligible for a clinical trial.Modelling prognostic factors in advanced pancreatic cancerClinical impact of pentraxin family expression on prognosis of pancreatic carcinoma.Long term survivors with metastatic pancreatic adenocarcinoma treated with gemcitabine: a retrospective analysisValidation of C-reactive protein levels as a prognostic indicator for survival in a large cohort of pancreatic cancer patients.Prognostic nomogram for nonresectable pancreatic cancer treated with gemcitabine-based chemotherapy.Predictive factors in pancreatic ductal adenocarcinoma: role of the inflammatory response.Chemotherapy-induced neutropenia as a prognostic factor in patients with unresectable pancreatic cancer.Prognostic model for survival based on readily available pretreatment factors in patients with advanced pancreatic cancer receiving palliative chemotherapy.Prognostic factors in japanese patients with advanced pancreatic cancer treated with single-agent gemcitabine as first-line therapy.Prognostic factors in patients with gemcitabine-refractory pancreatic cancer.CEA and CA-19.9 serum tumor markers as prognostic factors in patients with locally advanced (unresectable) or metastatic pancreatic adenocarcinoma: a retrospective analysis.Gemcitabine treatment in patients with inoperable locally advanced/metastatic pancreatic cancer and prognostic factors.Stent patency using competing risk model in unresectable pancreatic cancers inserted with biliary self-expandable metallic stent.A Survival Model in Locally Advanced and Metastatic Pancreatic Ductal Adenocarcinoma.Case Report: Long-Term Survival in Patients with Initial Lung-Only Metastasis from Pancreatic Adenocarcinoma.
P2860
Q33394190-0A193DF6-DC21-4804-9F58-B8C71E75820FQ33787820-A7C947FB-0C09-4002-AB96-FEFE7704DFD4Q34346758-68F66BEF-447D-4D4F-B51B-13FBC6ED3825Q35648973-58E3A90A-AF29-4E8D-901C-6FE041DD8D11Q35946922-5F764CBC-B600-4855-BCED-D54E5A19ABA6Q36063299-3950614E-FA53-4F70-9B8D-B4959EA85149Q36408348-76E54597-751B-498E-8370-10E5CA6F7CDCQ36561493-CF07107D-B2FD-48D6-BA3B-5D5DDBE9A2B1Q36615780-64614636-416B-4FCD-BD3E-DDB796697AB0Q36756383-EA182F89-98A3-4349-8F1A-D493D15BAB42Q36851983-4C78CF7E-38E9-415D-BC8D-8417F4873CE5Q36882688-A5CDEE61-C631-4541-86E0-5DB82BD99E32Q37081859-EF0C430F-D178-4650-8E65-C4D33FE6BB35Q37145924-928E1289-49E3-4A00-9E05-C49CE90D739EQ37459643-1F9D3F94-F32A-4887-98F7-958F48144B8EQ37711653-CD94F70E-9B7A-4D89-9ED0-2F7996A29B37Q40212563-2719EBF8-B984-4A06-9E64-54A4F79ACC33Q40330557-137C717B-B550-4C8B-A2E2-887780ED3967Q40784520-60407CA2-15D5-400E-9F95-75A18D6EC2AAQ43797985-92495A6C-740D-4F64-97D3-005B6BA9234EQ45233598-BEE425E6-E6C2-438E-9AD4-0292ACCBAB04Q45386745-1AC4FE15-5BA4-4D50-BD4D-4DCA465DF0ABQ46809079-3118A102-C11A-4586-A67B-8198023CB9DAQ48324395-3F502F45-DDC4-4F07-9959-8E40B68C5CC8Q52576032-4676DEE1-01EB-4811-90C0-B286B2D89059Q53213858-CD0E9C2C-D330-434B-94AC-F68D9F8CF4E2
P2860
Prognostic factors in patients with metastatic pancreatic adenocarcinoma receiving systemic chemotherapy.
description
2000 nî lūn-bûn
@nan
2000年の論文
@ja
2000年学术文章
@wuu
2000年学术文章
@zh-cn
2000年学术文章
@zh-hans
2000年学术文章
@zh-my
2000年学术文章
@zh-sg
2000年學術文章
@yue
2000年學術文章
@zh
2000年學術文章
@zh-hant
name
Prognostic factors in patients ...... ceiving systemic chemotherapy.
@en
type
label
Prognostic factors in patients ...... ceiving systemic chemotherapy.
@en
prefLabel
Prognostic factors in patients ...... ceiving systemic chemotherapy.
@en
P2093
P356
P1433
P1476
Prognostic factors in patients ...... ceiving systemic chemotherapy.
@en
P2093
P304
P356
10.1159/000012186
P577
2000-11-01T00:00:00Z